254 related articles for article (PubMed ID: 22434665)
1. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
[TBL] [Abstract][Full Text] [Related]
2. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy.
Deng Q; Su B; Ji X; Fang Q; Zhou S; Zhou C
Cancer Biomark; 2020; 27(3):313-323. PubMed ID: 31839603
[TBL] [Abstract][Full Text] [Related]
4. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
6. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
7. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
8. RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China.
Lin Q; Geng J; Ma K; Yu J; Sun J; Shen Z; Bao G; Chen Y; Zhang H; He Y; Luo X; Feng X; Zhu J
J Cancer Res Clin Oncol; 2009 Dec; 135(12):1675-84. PubMed ID: 19506903
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
Abratt RP; Lee JS; Han JY; Tsai CM; Boyer M; Mok T; Kim SW; Lee JS; Brnabic AJ; Reece WH; Lehnert M
J Thorac Oncol; 2006 Feb; 1(2):135-40. PubMed ID: 17409842
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
Ma X; Le Teuff G; Lacas B; Tsao MS; Graziano S; Pignon JP; Douillard JY; Le Chevalier T; Seymour L; Filipits M; Pirker R; Jänne PA; Shepherd FA; Brambilla E; Soria JC; Hainaut P;
J Thorac Oncol; 2016 Jun; 11(6):850-61. PubMed ID: 26899019
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine.
Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Manegold C; Lahm H
Lung Cancer; 2007 Apr; 56(1):115-23. PubMed ID: 17196704
[TBL] [Abstract][Full Text] [Related]
12. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
13. MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Levallet G; Dubois F; Fouret P; Antoine M; Brosseau S; Bergot E; Beau-Faller M; Gounant V; Brambilla E; Debieuvre D; Molinier O; Galateau-Sallé F; Mazieres J; Quoix E; Pujol JL; Moro-Sibilot D; Langlais A; Morin F; Westeel V; Zalcman G
Oncotarget; 2017 Jan; 8(3):4313-4329. PubMed ID: 28008145
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
[TBL] [Abstract][Full Text] [Related]
15. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M
Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993
[TBL] [Abstract][Full Text] [Related]
16. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer.
Kim DH; Kim JS; Park JH; Lee SK; Ji YI; Kwon YM; Shim YM; Han J; Park J
Cancer Res; 2003 Oct; 63(19):6206-11. PubMed ID: 14559805
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
Wang J; Wang B; Chen X; Bi J
Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
[TBL] [Abstract][Full Text] [Related]
18. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).
Ji M; Guan H; Gao C; Shi B; Hou P
BMC Cancer; 2011 Apr; 11():147. PubMed ID: 21507233
[TBL] [Abstract][Full Text] [Related]
19. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
Ramirez JL; Rosell R; Taron M; Sanchez-Ronco M; Alberola V; de Las Peñas R; Sanchez JM; Moran T; Camps C; Massuti B; Sanchez JJ; Salazar F; Catot S;
J Clin Oncol; 2005 Dec; 23(36):9105-12. PubMed ID: 16361617
[TBL] [Abstract][Full Text] [Related]
20. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.
Kontic M; Stojsic J; Jovanovic D; Bunjevacki V; Ognjanovic S; Kuriger J; Puumala S; Nelson HH
Clin Lung Cancer; 2012 Jul; 13(4):297-303. PubMed ID: 22169480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
